Fibrinolysis Resistance in Infection and Trauma
Key facts
- Who runs it
- Anders Aneman
- Where
- Australia4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 1 Jun 2024
- Planned end
- 1 Jun 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Viscoelastometric assessment of fibrinolysis
- Record updated
- 8 November 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Other criteria
- Sepsis/Septic shock Inclusion Criteria:
- Admission to ICU, needing at least one organ supportand principally for the management of clinically suspected Sepsis or Septic shock according to Spesis-3 criteria (including SARS-COV-2)
- Expected to remain in ICU and survive beyond the day after tomorrow; Sepsis Exclusion Criteria:
- On oral anticoagulant/antiplatelet therapy
- Not for full, active ICU support
- Death is deemed inevitable within 24 hrs; Trauma Inclusion Criteria:
- Trauma is the principal diagnosis on ICU admission
- Expected to remain in ICU and survive beyond the day after tomorrow
- Receiving respiratory support at the time of ICU admission - high-flow nasal prongs, non-invasive or invasive ventilation
- Already received, or considered at risk of needing a blood product transfusion within 24 hrs of injury; Trauma Exclusion Criteria:
- Nursing home resident
- Unsurvivable head injury
- Not for full, active ICU support
- Death is deemed inevitable within 24 hrs
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Blood coagulation disorders are often seen in critically ill patients e.g. with severe infection or following extensive injury, that can lead to life threatening events as a result of excessive blood clot formation leading to organ failure. This study aims to use Viscoelastic Testing (VET) technology to detect patients at risk of excessive blood blot formation at the bedside, test new blood coagulation drugs, and guide life-saving use of blood modifying treatments.
The 2 groups in the trial
- Sepsis/Septic shock
According to Sepsis-3 definitions (including SARS CoV-2 as pathogen); expected to remain in ICU and survive beyond the day after tomorrow and for full, active ICU treatment; arterial and secure venous access established or imminent as part of standard care; not on oral anticoagulant/antiplatelet therapy.
Treatment: Viscoelastometric assessment of fibrinolysis
- Severe Trauma
Admitted via the Emergency Department resuscitation bay requiring trauma team response; deemed at risk of significant blood loss and where transfusion of blood products i considered in the ED during the acute phase of the resuscitation by a senior clinician; expected to remain in ICH and survive beyond the day after tomorrow and for full, active ICU treatment; Not on oral anticoagulant/antiplatelet therapy. A clinical based inclusion approach is the most pragmatic means of patient selection and can be objectively supported by routine blood tests demonstrating poor oxygen supply to the organs. Exclusion criteria: unsurvivable head injury.
Treatment: Viscoelastometric assessment of fibrinolysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Investigating Fibrinolysis Resistance in Sepsis Using High-Multiplex Plasma Proteomics: A Statistical Analysis Plan.Acta anaesthesiologica Scandinavica, 2026
- Record updated
- 8 November 2024